Pheochromocytoma: From the bench to the surgery

Minerva Chirurgica

Volumn 69, Issue 2 SUPPL.1, 2014, Pages 97-103

  Accardo, G ^a   Esposito, D ^a   Barbato, F ^a   De Bellis, A ^a   Iorio, S ^a   Amoresano Paglionico, V ^a   Colella, C ^a   Dello Iacovo, A ^a   Selvaggi, F ^a   Docimo, G ^a   Conzo, G ^a   Pasquali, D ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Operative; Pheochromocytoma; Proto oncogene proteins c ret; Surgical procedures

Indexed keywords

EID: 84907422036     PISSN: 00264733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clinl Endocrinol Metab 2001;86:5210-6.
2. Stenstrom G, Svardsudd K Pheocromocytoma in Sweden, 1958-81. An analysis of the National Cancer Registry Data. Acta Med Scand 1986;220:225-32.
3. Smythe GA, Edwards G, Graham P, Lazarus L. Biochemical diagnosis of pheocromocytoma by simultaneous measurement of urinary excretion of epinephrine and norepinephrine. Clinical chemistry 1992;38:486-92.
4. Kirmani S, Young WF. Hereditary paraganglioma-pheocromocytoma syndromes. In: Pagon RA, Bird TD, Dolan CR et al. editors. GeneReviews. Seattle, WA: University of Washington; 1993 [Internet]. Available from: http://www.ncbi.nlm. nih.gov/books/NBK1548 [cited 2012; Aug 30].
5. Manger WM, Gifford RW. Background and importance and diagnosis. In: Manger WM, Gifford RW, editors. Clinical and Experimental pheocromocytoma. 2nd edition. Cambrige: Blackwell Science; 1996. p. 205-332.
6. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G et al. Germ-line mutations in nonsyndromic pheocromocytoma. N Engl J Med 2002;346:1459-66.
7. Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1. Nat Rev Cancer 2005;5:367-75.
8. Carling T. Multiple endocrine neoplasia syndrome: genetic basis for clinical management. Curr Opin Oncol 2005;17:7-12.
9. Schussheim DH, Skarulis MC, Agarwal SK, Simonds WF, Burns AL, Spiegel AM et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 2001;12:173-8.
10. Peczkowska M, Januszewicz A. Multiple endocrine neoplasia type 2. Fam Cancer 2005;4:25-36.
11. Califano D, Monaco C, de Vita G, D'Alessio A, Dathan NA, Possenti R et al. Activated RET/PTC oncogene elicits immediate early and delayed response genes in PC12 cells. Oncogene 1995;11:107-12.
12. Tessitore A, Sinisi AA, Pasquali D, Cardone M, Vitale D, Bellastella A et al. A novel case of multiple endocrine neoplasia type 2A associated with three de novo mutations of the RET protooncogene. J Clin Endocrinol Metab 1999;10:3522-7.
13. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000;287:848-51.
14. Bayley JP, Devilee P, Taschner PE. The SDH mutation database: an online resource for succinate dehydrogenase sequence variants involved in pheocromocytoma, paraganglioma and mitochondrial complex II deficiency. BMC Med Genet 2005;6:39.
15. Fishbein L, Nathanson KL. Pheocromocytoma and paraganglioma: understanding the complexities of the genetic background. Cancer Genet 2012;205:1-11.
16. Pasini B, Stratakis CA. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J Intern Med 2009;266:19-42.
17. Astuti D, Douglas F, Lennard TW, Aligianis IA, Woodward ER, Evans DG et al. Germline SDHD gene mutation in familial PHEO. Lancet 2001;357:1181-2.
18. Eng C, Kiuru M, Fernandez MJ, Aaltonen LA. A role of mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev Cancer 2003;3:193-202.
19. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. Jama 2004;292:943-51.
20. Baysal BE. Mitochondrial complex II and genomic imprinting in inheritance of paraganglioma tumors. Biochim Biophys Acta 2013;1827:573-7.
21. Lefebvre M, Foulkes WD. PHEO and paraganglioma syndromes: genetics and management update Curr Oncol 2014;21:8-17.
22. Jafri M, Maher ER. The genetics of phaeochromocytoma: using clinical features to guide genetic testing. Eur J Endocrinol 2012;166:151-8.
23. Gimenez-Roqueplo AP, Dahia PL, Robledo M. An update on the genetics of paraganglioma, PHEO, and associated hereditary syndromes. Horm Metab Res 2012;44:328-33.
24. Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 2007;92:3321-5.
25. Igreja S, Chahal HS, Akker SA, Gueorguiev M, Popovic V, Damjanovic S, Burman P et al. Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations. Clin Endocrinol 2009;70:259-64.
26. Pellegata NS. MENX. Ann Endocrinol 2012;73:65-70.
27. Pasquali D, Circelli L, Faggiano A, Pancione M, Ren-zullo A, Elisei R et al. CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma. Eur J Endocrinol 2011;64:397-404.
28. Alevizaki M, Stratakis CA Multiple endocrine neoplasias: advances and challenges for the future. J Intern Med 2009;266:1-4.
29. Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K. North American Neuroendocrine Tumor Society (NANETS). The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: PHEO, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39:775-83.
30. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R et al. Malignant pheocromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988;109:267-73.
31. Conzo G, Musella M, Corcione F, De Palma M, Ferraro F, Palazzo A, Napolitano S et al. Laparoscopic adrenalectomy, a safe procedure for pheochromocytoma. A retrospective review of clinical series. Int J Surg. 2013;11:152-6.
32. ConzoG, Musella M, Corcione F, De Palma M, Avenia N, Milone M et al. Laparoscopic treatment of pheochromocytomas smaller or larger than 6 cm. A clinical retrospective study on 44 patients. Laparoscopic adrenalectomy for pheochromocytoma. Ann Ital Chir. 2013;84:417-22.
33. Druce MR1, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res 2009;41:697-702.
34. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA et al. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheocromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab. 2009;94:386-91.
35. Joshua AM, Ezzat S, Asa SL, Evans A, Broom R, Freeman M, Knox JJ. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/PHEO. J Clin Endocrinol Metab.2009;94:5-9.
36. Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J et al. Phase II study of high-dose [131I] metaiodobenzylguanidine therapy for patients with metastatic PHEO and paraganglioma. J Clin Oncol 2009;27:4162-8.